Entenole, a new 1.1 breast cancer drug, enters CDE

Entenole is the first HDAC inhibitor to obtain positive results in phase II clinical randomized controlled trials of breast cancer Now, as a new drug of class 1.1, entenole is sponsored by CDE and entered the evaluation center Entinostat, a class 1.1 new drug of Yiteng Pharmaceutical (Taizhou) Co., Ltd., was undertaken by CDE on March 3, 2015 and entered the evaluation center, involving the acceptance numbers of cxhl1500230, cxhl1500231 and cxhl1500232 What's entenole? Entenole is a histone deacetylase (HDAC) inhibitor in research, which is used in the treatment of advanced breast cancer (stage III) and non-small cell lung cancer (stage II) The drug, developed by syndax pharmaceutical in the United States, was recognized by FDA as a breakthrough therapy in 2013 The reason why the drug was approved by FDA is its gratifying phase II clinical trial results Results of clinical trials of entenole the results of phase II clinical trials of entenole showed that the combination of entenole and exemestane significantly prolonged the progression free and total survival time in postmenopausal patients with local recurrence or estrogen receptor positive metastatic breast cancer As the first HDAC inhibitor with positive results in phase II clinical randomized controlled trials of breast cancer, entenole is undoubtedly a heavyweight product Syndex, on the other hand, has licensed the potential drug in China to Yiteng Now, entenole has applied for clinical application in China as a new class 1.1 drug and entered the evaluation center As for Yiteng pharmaceutical, in addition to entenole, Yiteng pharmaceutical has been cooperating with multinational pharmaceutical companies since 2004, reaching exclusive distribution rights agreements for nearly 20 drugs, and signed asset purchase agreements with act biotech for three small molecule drugs Among these drugs, anti-tumor drugs are as popular as ever Yiteng pharmaceutical, a company invested by domain associates, waupada capital and Sequoia Capital, has gradually shifted from clinical nutrition, respiratory system and other fields to the field of anti-tumor, with more and more focus.